| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
In this study, to develop the novel therapy for osteoporosis, regulatory cells for osteoclastogenesis were characterized. A removal of regulatory cells in peritoneal cavity resulted in the reduction of the osteoclatogenesis from bone marrow cells for more than 1 year. A removal of T lineage cells expressing CD4, CD8a, or CD5, but not B220, CD11b, CD11c, NK1.1, or IL7Ra in the bone marrow also reduced the osteoclastogenesis of bone marrow cells. These observations were confirmed by using mutant mice lacking T cells or T and B cells. Moreover, mice carrying T cell antigen receptor-transgene but not Btk mutation were affected a hypotonic treatment in the peritoneal cavity. Taken together, the osteoclastogenesis is suggested to be regulated by two-related systems presented in extra-medullary and intra-medullary sites.
|
